Investor Presentation Q1 2023

Novo NordiskⓇ 95 Investor presentation First three months of 2023 Alzheimer's disease patient journey is complex and underscores key barriers to overcome for Novo Nordisk to be successful Significant and growing Million unmet need Hurdles 80 60 40 40 Y Y Early symptoms dismissed as normal ageing AD prevalence Complex tests and limited screening/ diagnosing skills Lack of prognostic markers and simple tests Limited DMT options Few patients receiving diagnosis 20 20 0 Prevalence Diagnosed Eligible patients patients MCI Mild dementia Note: MCI and Mild dementia in the graph are both due to AD. • • Support healthcare system preparedness Larger number of AD patients expected to enter the system May lead to significant bottle- necks and delay to patient care Market preparation priorities Increase diagnosis rate Support NITs development, e.g. blood-based/digital biomarkers Increase AD education and access to screening tools for PCPs and HCP insight High expected investment level ○ Low expected investment level Evidence generation AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; DMT: Disease-modifying treatment; PCP: primary care physicians; NITs: Non-invasive diagnostics; HCP: Healthcare professional Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460) Evidence to better understand the • impact of delaying disease progression role of neuroinflammation in disease progression

View entire presentation